Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05600816

SurmodiCs Pounce Venous THrOMbectomy System Post Market Clinical Follow Up Study

This is an open label, prospective, non-randomised, multi-centre post market study of the POUNCE Venous Thrombectomy system for de-clotting in the peripheral vasculature (e.g., iliofemoral veins).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

This PMCF study is designed to further evaluate the safety and performance of the POUNCE Venous Thrombectomy system in the treatment of patients with symptomatic peripheral vascular thrombus through removal of thrombus. The study will collect both qualitative and quantitative data recorded by the investigators during the procedure to further evaluate safety and performance of the device.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals aged 18 years or older
  • Patients with peripheral vascular thrombus (e.g., iliofemoral) as confirmed by Doppler Ultrasonography (DUS)
  • Voluntary informed written consent, given before performance of any clinical investigation-related procedure not part of standard medical care, and with the understanding that consent may be withdrawn at any time without prejudice to future medical care
  • Patients who would likely experience benefit from mechanical thrombus removal

Exclusion criteria

  • Presence of a stent in the target vein
  • Known aggressive hypercoagulable states such as antiphospholipid antibody syndrome, Protein C/S Deficiency, Antithrombin deficiency, homozygous prothrombin gene mutation or homozygous Factor V Leiden
  • Limb-threatening circulatory compromise
  • Known symptomatic Pulmonary Embolism at the time of enrollment with or without severe RV dysfunction
  • Patients with a positive COVID test result at the time of the procedure
  • Patients who, according to the investigator, have a venous thrombus that may be associated with a prior COVID infection
  • History of, or active heparin induced thrombocytopenia (HIT)
  • Inability to withstand endovascular procedures
  • Life expectancy < 1 year
  • Participation in any other drug or device studies that have not reached the primary endpoint follow up, which could compromise the results of either trial
  • Patient has any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol
  • Likely inability to comply with the protocol or cooperate fully with the investigator and site personnel
  • Known or suspected abuse of alcohol, narcotics or non-prescription drugs that would jeopardize study outcomes in the Investigator's opinion
  • Inability to provide informed consent or to comply with study assessments (e.g., due to cognitive impairment or geographic distance)

Treatment and study plan

Pounce Venous Thrombectomy System

Device

The device is indicated for mechanical de-clotting and controlled and selective infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature.

Primary outcomes

  1. Device Performance

    Time frame: 30 days, 1 year

    Successful preparation and use of the device to achieve flow restoration, i.e., elimination of a minimum of 50% thrombus (SIR Grade II or Grade III) in the treated target venous segment.

Study contacts

Contact information is provided by the study sponsor or research team.

Aliza Avalos

CONTACT

[email protected]

209-485-2072

Nusrath Sultana, MD

CONTACT

[email protected]

763-777-2737

Sponsors and collaborators

Lead sponsor

SurModics, Inc.

Industry

Registry information

Official study title

CHOMP: SurmodiCs Pounce Venous THrOMbectomy System Post Market Clinical Follow Up Study

Acronym: CHOMP

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Nov 1, 2022
Registry last updated
May 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.